Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pulse Biosciences Inc PLSE

Healthcare Medical Devices
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it... see more

Recent & Breaking News (NDAQ:PLSE)

Pulse Biosciences Reports Second Quarter 2020 Financial Results

Business Wire August 10, 2020

Pulse Biosciences, Inc. Appoints Richard van den Broek to Board of Directors

Business Wire August 6, 2020

Pulse Biosciences Schedules Second Quarter 2020 Financial Results Conference Call for August 10, 2020

Business Wire July 27, 2020

Nano-Pulse Stimulation(TM) Technology Produces Favorable Results in Several Clinical Studies Presented at the 2020 Laser Medicine and Surgery Virtual Annual Conference

Business Wire July 1, 2020

Pulse Biosciences, Inc. Announces Closing of $30 Million Rights Offering

Business Wire June 16, 2020

Pulse Biosciences, Inc. Announces Further Details of Oversubscribed Rights Offering

Business Wire June 10, 2020

Pulse Biosciences, Inc. Announces Preliminary Results for Its Oversubscribed Rights Offering

Business Wire June 8, 2020

Pulse Biosciences, Inc. Announces Commencement of Rights Offering

Business Wire May 14, 2020

Pulse Biosciences Reports First Quarter 2020 Financial Results

Business Wire May 11, 2020

Pulse Biosciences, Inc. Announces Updated Structure, Dates and Pricing Terms for Rights Offering

Business Wire May 1, 2020

Pulse Biosciences Schedules First Quarter 2020 Financial Results Conference Call for May 11, 2020

Business Wire April 29, 2020

Pulse Biosciences Files Registration Statement for Rights Offering

Business Wire April 6, 2020

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Business Wire March 17, 2020

Pulse Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results

Business Wire March 16, 2020

Pulse Biosciences Schedules Fourth Quarter and Full Year 2019 Financial Results Conference Call for March 16, 2020

Business Wire March 9, 2020

Pulse Biosciences to Participate in the Cowen Health Care Conference

Business Wire February 19, 2020

Pulse Biosciences Provides Update on FDA 510(k) Submission for the CellFX System in Dermatology

Business Wire February 13, 2020

Pulse Biosciences to Present Data on Nano-Pulse Stimulation Technology for Nodular Basal Cell Carcinoma at IMCAS World Congress 2020

Business Wire January 29, 2020

Pulse Biosciences Updates on Regulatory Progress

Business Wire December 18, 2019

Pulse Biosciences Grants Equity Incentive Awards to New Employees

Business Wire December 16, 2019